Questionnaire-based study of COVID-19 vaccination induced headache: evidence of clusters of adverse events.
Adverse events
Covid-19 vaccination
Headache
Side effects
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
02 Mar 2024
02 Mar 2024
Historique:
received:
31
10
2023
accepted:
23
02
2024
medline:
3
3
2024
pubmed:
3
3
2024
entrez:
2
3
2024
Statut:
epublish
Résumé
The adverse events (AEs) after a Coronavirus disease 2019 (Covid-19) Pfizer-Biotech mRNA vaccination present a medical and epidemiological issue of increasing interest. Headache is the most frequent neurological adverse effect and generally the third most common adverse event after a Covid-19 vaccination, but only a few studies focus on the link between headache and other AEs after vaccination. This study aims to investigate the correlation between headaches and Covid-19 vaccination, as well as the possible links between headaches and other AEs after Covid-19 vaccination, thereby helping the management of AEs and avoiding further occurrences. This study is based on a published questionnaire survey of 1,402 healthcare workers. Our study focused on the 5 questions including 12 AEs and headaches extracted from the questionnaire post the first and second Covid-19 vaccination. The severity of the 12 AEs and headaches could be classified by the participants on a five-step scale: "Not at all", "Little", "Average", "Quite", and "Very" (abbreviated as "N", "L", "A", "Q", "V"). We used the Bowker test to study the comparison of headache severity, indicated on a 5-point Likert scale between the first and second vaccinations. We applied an ordinal logistic regression to the 5 categories with headache severity serving as the dependent variable and the ratings of the other 12 AEs serving as the independent variable to further explore to what extent the severity of the 12 AEs is associated with the severity of headaches. Receiver Operating Characteristic (ROC) analysis was conducted to evaluate the predictive value of the ratings of the 12 AEs to headache severity. We found that participants rated their headaches as more severe after the second vaccination, and participants who reported experiencing fatigue, flu-like symptoms, pain at the injection site, known tension-type headache, fever, dizziness/balance problems and known migraine are associated with headache symptoms. There are clusters of headache-associated AEs post Covid-19 vaccination. The association of various AEs with headaches may be due to similar causative mechanisms.
Sections du résumé
BACKGROUND
BACKGROUND
The adverse events (AEs) after a Coronavirus disease 2019 (Covid-19) Pfizer-Biotech mRNA vaccination present a medical and epidemiological issue of increasing interest. Headache is the most frequent neurological adverse effect and generally the third most common adverse event after a Covid-19 vaccination, but only a few studies focus on the link between headache and other AEs after vaccination. This study aims to investigate the correlation between headaches and Covid-19 vaccination, as well as the possible links between headaches and other AEs after Covid-19 vaccination, thereby helping the management of AEs and avoiding further occurrences.
METHODS
METHODS
This study is based on a published questionnaire survey of 1,402 healthcare workers. Our study focused on the 5 questions including 12 AEs and headaches extracted from the questionnaire post the first and second Covid-19 vaccination. The severity of the 12 AEs and headaches could be classified by the participants on a five-step scale: "Not at all", "Little", "Average", "Quite", and "Very" (abbreviated as "N", "L", "A", "Q", "V"). We used the Bowker test to study the comparison of headache severity, indicated on a 5-point Likert scale between the first and second vaccinations. We applied an ordinal logistic regression to the 5 categories with headache severity serving as the dependent variable and the ratings of the other 12 AEs serving as the independent variable to further explore to what extent the severity of the 12 AEs is associated with the severity of headaches. Receiver Operating Characteristic (ROC) analysis was conducted to evaluate the predictive value of the ratings of the 12 AEs to headache severity.
RESULTS
RESULTS
We found that participants rated their headaches as more severe after the second vaccination, and participants who reported experiencing fatigue, flu-like symptoms, pain at the injection site, known tension-type headache, fever, dizziness/balance problems and known migraine are associated with headache symptoms.
CONCLUSIONS
CONCLUSIONS
There are clusters of headache-associated AEs post Covid-19 vaccination. The association of various AEs with headaches may be due to similar causative mechanisms.
Identifiants
pubmed: 38431578
doi: 10.1186/s12883-024-03583-6
pii: 10.1186/s12883-024-03583-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Informations de copyright
© 2024. The Author(s).
Références
WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. https://covid19.who.int/ . Accessed 3 Jul 2023
Fiolet T, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21.
doi: 10.1016/j.cmi.2021.10.005
pubmed: 34715347
Shapiro B, David S et al. Immediate side effects of comirnaty COVID-19 vaccine: a nationwide survey of vaccinated people in Israel, December 2020 to March 2021. Euro Surveill. 2022;27(13).
Andrzejczak-Grządko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25(12):4418–21.
pubmed: 34227078
Sampaio Rocha-Filho PA, et al. Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study. J Headache Pain. 2022;23(1):2.
doi: 10.1186/s10194-021-01367-8
pubmed: 34979899
pmcid: 8721484
Lee DS, et al. Significance of digestive symptoms after COVID-19 vaccination: a retrospective single-center study. Am J Emerg Med. 2022;58:154–8.
doi: 10.1016/j.ajem.2022.05.044
pubmed: 35691237
pmcid: 9144838
Al-Ali D, et al. Cardiovascular and haematological events post COVID-19 vaccination: a systematic review. J Cell Mol Med. 2022;26(3):636–53.
doi: 10.1111/jcmm.17137
pubmed: 34967105
Cocores AN, Goadsby PJ, Monteith TS. Post-vaccination headache reporting: trends according to the vaccine adverse events reporting system. Headache. 2023;63(2):275–82.
doi: 10.1111/head.14458
pubmed: 36651626
McAlpine LS, Zubair AS. Neurological sequelae of vaccines. Neurol Sci. 2023;44(5):1505–13.
doi: 10.1007/s10072-022-06581-z
pubmed: 36622478
pmcid: 9838503
Castaldo M, et al. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. J Headache Pain. 2022;23(1):41.
doi: 10.1186/s10194-022-01400-4
pubmed: 35361131
pmcid: 8969402
Göbel CH, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 2021;3(3):fcab169.
doi: 10.1093/braincomms/fcab169
pubmed: 34405142
pmcid: 8344581
Chen L, et al. The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose. Hum Vaccin Immunother. 2023;19(1):2176643.
doi: 10.1080/21645515.2023.2176643
pubmed: 36798968
pmcid: 10026905
García-Azorín D, et al. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain. 2021;22(1):108.
doi: 10.1186/s10194-021-01324-5
pubmed: 34535076
pmcid: 8446734
Zhelyazkova A et al. Are we prepared for the next pandemic? Management, systematic evaluation and lessons learned from an in-hospital COVID-19 vaccination centre for healthcare workers. Int J Environ Res Public Health. 2022;19(23).
Venables W, Ripley B. Modern applied statistics with S. Springer, New York: ISBN 0-387-95457-0. 2002.
Sekiguchi K, et al. Incidence of headache after COVID-19 vaccination in patients with history of headache: a cross-sectional study. Cephalalgia. 2022;42(3):266–72.
doi: 10.1177/03331024211038654
pubmed: 34407651
Silvestro M et al. Headache worsening after COVID-19 vaccination: an online questionnaire-based study on 841 patients with migraine. J Clin Med. 2021;10(24).
Göbel CH, et al. Headache attributed to vaccination against COVID-19 (coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study. Pain Ther. 2021;10(2):1309–30.
doi: 10.1007/s40122-021-00296-3
pubmed: 34313952
pmcid: 8314854
Ekizoglu E, et al. The characteristics of COVID-19 vaccine-related headache: clues gathered from the healthcare personnel in the pandemic. Cephalalgia. 2022;42(4–5):366–75.
doi: 10.1177/03331024211042390
pubmed: 34510919
Boum Y, et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet Infect Dis. 2021;21(8):1089–96.
doi: 10.1016/S1473-3099(21)00132-8
pubmed: 33773618
pmcid: 7993929
Bolay H, et al. Are migraine patients at increased risk for symptomatic coronavirus disease 2019 due to shared comorbidities? Headache. 2020;60(10):2508–21.
doi: 10.1111/head.13998
pubmed: 33124044
Trigo J, et al. Cytokine and interleukin profile in patients with headache and COVID-19: a pilot, CASE-control, study on 104 patients. J Headache Pain. 2021;22(1):51.
doi: 10.1186/s10194-021-01268-w
pubmed: 34088273
pmcid: 8177251
Caronna E, et al. Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: a comprehensive review. Cephalalgia. 2023;43(1):3331024221131337.
doi: 10.1177/03331024221131337
pubmed: 36606562
Shahid S, et al. Post-vaccination (COVID-19) impacts in healthcare personnel. Pak J Pharm Sci. 2021;34(5Supplementary):1957–62.
pubmed: 34836866
Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–93.
doi: 10.1016/S0140-6736(20)32466-1
pubmed: 33220855
Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
Yesuf EA, et al. Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: a cross-sectional study. Front Public Health. 2022;10:937794.
doi: 10.3389/fpubh.2022.937794
pubmed: 35928493
pmcid: 9343757
Valencia BM, et al. The severity of the pathogen-induced acute sickness response is affected by polymorphisms in genes of the NLRP3 inflammasome pathway. Brain Behav Immun. 2021;93:186–93.
doi: 10.1016/j.bbi.2021.01.005
pubmed: 33434563
pmcid: 7794598
He W, et al. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. J Neuroinflammation. 2019;16(1):78.
doi: 10.1186/s12974-019-1459-7
pubmed: 30971286
pmcid: 6456991
Suwanwela NC, et al. Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series. J Headache Pain. 2022;23(1):13.
doi: 10.1186/s10194-022-01385-0
pubmed: 35062869
pmcid: 8777408
Garces KN, et al. Headache after vaccination: an update on recent clinical trials and real-world reporting. Curr Pain Headache Rep. 2022;26(12):895–918.
doi: 10.1007/s11916-022-01094-y
pubmed: 36418848
pmcid: 9685066
Straube A, Ruscheweyh R, Klonowski T. Headache associated with COVID-19 vaccination: how to classify?. Schmerz. 2023:1–9.